Tags : 5F9

Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven

Tuba Khan July 12, 2019

Shots: Forty Seven to receive ~ $15.8M up front, ~$104M as development and commercial milestones and royalties on sales of 5F9 in selected territories and will retain WW rights of […]readmore

Tags : 5F9

Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : 5F9

﻿Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven